Read More Pharma Industry News Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically… byPallavi MadhirajuJuly 30, 2023